{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:06:01Z","timestamp":1791090361733,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T00:00:00Z","timestamp":1269820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neuroscience &amp; Therapeutics"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:p>Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Gastrointestinal side effects, difficulty accessing therapeutic doses and poor patient compliance have been identified as barriers to effective treatment with these substances. The rivastigmine transdermal patch provides continuous delivery of drug through the skin into the bloodstream, avoiding the fluctuations in plasma concentration associated with oral administration. This pharmacokinetic profile is associated with reduced side effects, resulting in easier access to expected target doses. These benefits, along with other practical advantages of the transdermal patch, may contribute to enhanced patient compliance. Here, we present a review of the current literature on rivastigmine patch, and offer advice based on our own collective clinical experience. Rivastigmine patch provides an efficient option for managing patients with AD, to be considered among the first line therapies for the disease.<\/jats:p>","DOI":"10.1111\/j.1755-5949.2010.00141.x","type":"journal-article","created":{"date-parts":[[2010,12,20]],"date-time":"2010-12-20T14:39:55Z","timestamp":1292855995000},"page":"246-253","source":"Crossref","is-referenced-by-count":29,"title":["Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease"],"prefix":"10.1111","volume":"16","author":[{"given":"Murat","family":"Emre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bernabei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Blesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Dani\u00ebls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Dziadulewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"F\u00f6rstl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gabryelewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lindesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mart\u00ednez\u2010Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Monsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Tsolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"Van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X233403"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01401.x"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912040-00005"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7184.633"},{"key":"e_1_2_10_6_2","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease","volume":"1","author":"Corey\u2010Bloom J","year":"1998","journal-title":"Int J Geriatr Psychopharmacol"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.099424"},{"issue":"1","key":"e_1_2_10_9_2","first-page":"S26","article-title":"Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease","volume":"1","author":"Schneider LS","year":"1998","journal-title":"Int J Geriatr Psychopharmacol"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802542690"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1788"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200203000-00013"},{"key":"e_1_2_10_13_2","first-page":"45","article-title":"The tolerability and safety of cholinesterase inhibitors in the treatment of dementia","volume":"127","author":"Inglis F","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200304000-00011"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199813050-00005"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03337721"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100242"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253438"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.11.1457"},{"key":"e_1_2_10_20_2","first-page":"68","article-title":"Dose\u2010response effect of rivastigmine in the treatment of Alzheimer's disease","volume":"2","author":"Anand R","year":"2000","journal-title":"Int J Geriatr Psychopharmacol"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020200089"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.4.563"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297748"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02052.x"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31818b1c2c"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533317509333037"},{"key":"e_1_2_10_27_2","unstructured":"Rivastigmine (Exelon\u00ae).Summary of product characteristics.Available from:http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Exelon\/H\u2010169\u2010PI\u2010en.pdf[Assessed July 15 2009."},{"key":"e_1_2_10_28_2","volume-title":"US prescribing information","author":"Exelon Patch\u00ae","year":"2009"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v08n0501"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200828060-00004"},{"key":"e_1_2_10_31_2","article-title":"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: A 26\u2010week, open\u2010label, prospective trial (Study ENA713B US32)","author":"Olin JT","year":"2009","journal-title":"Int J Geriatr Psychiatry"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0075-9"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1806"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2004.11.022"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53384_9.x"},{"key":"e_1_2_10_36_2","first-page":"449","article-title":"Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine [In Spanish]","volume":"43","author":"Sicras\u2010Mainar A","year":"2006","journal-title":"Rev Neurol"},{"key":"e_1_2_10_37_2","first-page":"231","article-title":"Drug persistency patterns for patients treated with rivastimgine or donepezil in usual care settings","volume":"11","author":"Mauskopf JA","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00524.x"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200607000-00005"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.1.37"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623050-00001"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2010.00141.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5949.2010.00141.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:49:13Z","timestamp":1698767353000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2010.00141.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1755-5949.2010.00141.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00141.x","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}